iad Ali, MD, DPhil, director of the DeMatteis Cardiovascular Institute and director investigational interventional cardiology, St. Francis Hospital and Heart Center, explains how coronary computed tomography angiography (CCTA) offers a shift in cardiac care and interventional cardiology because of the information it offers on plaque burden and ischemia based on fractional flow reserve CT (FFR-CT). #TCT #YesCCT

CCTA becoming an essential tool for interventional cardiologists

Ziad Ali, MD, explains how coronary computed tomography angiography is creating a major shift in cardiac care.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Cardiologists propose new 'coronary risk zone' approach for redo TAVR planning

Redo TAVR can be challenging, requiring a significant amount of preprocedural CT planning. This proposed framework was designed to simplify that planning and help interventional cardiologists thrive. 

iron bioresorbable scaffold Biotyx Medical

Ultrathin iron bioresorbable scaffold shows promise in first randomized trial

An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC

Nathaniel Lebowitz, MD, in charge of preventive cardiology at Hackensack University Medical Center, and assistant professor of internal medicine at Hackensack Meridian School of Medicine, gives an overview of where things are at with lipoprotein (a) awareness, testing and drug development. He and is working on the American Heart Associations (AHA) Lp(a) Discovery Project to expand awareness to both physicians and patients. #AHA #LPA

Cardiologist discusses Lp(a), the CVD risk factor responsible for many surprise heart attacks

Cardiologist Nathaniel Lebowitz, MD, reviews the latest updates in lipoprotein(a) awareness, testing and drug development.

warning safety alert recall healthcare issue

Safety update: New recommendations for managing patients with high-risk defibrillation leads

HRS has shared an updated guidance on managing Boston Scientific defibrillation leads at risk of experiencing a significant malfunction. The issue, first reported in July 2025, is believed to impact approximately 350,000 leads still being used today.

Andres Cordova, MD, cardiology fellow, University of Vermont Medical Center, explains a study of registry and outcomes data on the use of Impella hemodynamic support in elderly STEMI patients with cardiogenic shock.

Impella use fails to improve mortality in elderly patients

The Impella CP heart pump is being used more and more to treat cardiogenic shock, and the benefits are clear. For many older patients, however, the technology seem to fall short. 

Boston, the home of AF Symposium 2026

Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations. 

cardiologists heart doctors

TAVR valve for AR , a recent Edwards acquisition, delivers long-term value

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.